Highly Recommend
Awesome APP, provides clinically relevant information at your fingertips.
Medeligo
Published by: LiveMed Media
Description
Medeligo® provides instant access to the latest oncology literature and information for treatment, procedure, testing, and management information across all oncology subspecialties.
FINGERTIP ACCESS TO THE LATEST ONCOLOGY INFORMATION
- AI-powered search engineered by technologists and medical librarians
- Effortless UI gets to answers in seconds
- Covers more than 2,000 solid tumors and cancers, including the WHO Classification of Tumours
- Real-time searches provide the latest information available
- Searches only the most trusted medical journals, databases, and information resources
- Primary source material: unfiltered, unbiased, uncurated
Benefits include:
- Find and read the latest oncology literature in seconds
- Watch relevant videos and browse images
- Prepare for patient rounds, consults, and surgeries
- Answer patient-specific questions quickly at tumor boards
- Share, print, or save articles
Limited introductory price of $49.99 (Reg. $149.99) for the All Access (1 year) subscription — includes a risk-free 3-month trial.
To learn more, please visit www.medeligo.com.
After the free trial period, your subscription will continue for $49.99/year, and your iTunes account will be charged. If you do not wish to continue your subscription after your free trial ends, turn off auto-renew in your Account Settings 24 hours before the end of your free trial.
Subscriptions will automatically renew when they expire unless you turn off auto-renew at least 24 hours before the end of your subscription period. Your account will be charged $49.99 for renewal within 24 hours before the end of your subscription period. You can manage your subscription and turn off auto-renew by going to your Account Settings.
Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication, where applicable.
You can read more about our terms and conditions here:
Privacy policy: http://medeligo.com/privacy-policy/
Terms of service: http://medeligo.com/terms-of-service/
Hide
Show More...
FINGERTIP ACCESS TO THE LATEST ONCOLOGY INFORMATION
- AI-powered search engineered by technologists and medical librarians
- Effortless UI gets to answers in seconds
- Covers more than 2,000 solid tumors and cancers, including the WHO Classification of Tumours
- Real-time searches provide the latest information available
- Searches only the most trusted medical journals, databases, and information resources
- Primary source material: unfiltered, unbiased, uncurated
Benefits include:
- Find and read the latest oncology literature in seconds
- Watch relevant videos and browse images
- Prepare for patient rounds, consults, and surgeries
- Answer patient-specific questions quickly at tumor boards
- Share, print, or save articles
Limited introductory price of $49.99 (Reg. $149.99) for the All Access (1 year) subscription — includes a risk-free 3-month trial.
To learn more, please visit www.medeligo.com.
After the free trial period, your subscription will continue for $49.99/year, and your iTunes account will be charged. If you do not wish to continue your subscription after your free trial ends, turn off auto-renew in your Account Settings 24 hours before the end of your free trial.
Subscriptions will automatically renew when they expire unless you turn off auto-renew at least 24 hours before the end of your subscription period. Your account will be charged $49.99 for renewal within 24 hours before the end of your subscription period. You can manage your subscription and turn off auto-renew by going to your Account Settings.
Any unused portion of a free trial period, if offered, will be forfeited when the user purchases a subscription to that publication, where applicable.
You can read more about our terms and conditions here:
Privacy policy: http://medeligo.com/privacy-policy/
Terms of service: http://medeligo.com/terms-of-service/
In-Apps
- All Access (1 year)
- €29.99
Screenshots
Medeligo FAQ
-
Is Medeligo free?
Yes, Medeligo is free to download, however it contains in-app purchases or subscription offerings.
-
Is Medeligo legit?
Not enough reviews to make a reliable assessment. The app needs more user feedback.
Thanks for the vote -
How much does Medeligo cost?
Medeligo has several in-app purchases/subscriptions, the average in-app price is €29.99.
-
What is Medeligo revenue?
To get estimated revenue of Medeligo app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.
User Rating
App is not rated in Ireland yet.
Ratings History
Medeligo Reviews
Highly recommend!
So glad I found this app. How did I not know about it? It’s easy to use and provides fast access to information that I otherwise might not have time to find.
Wonderful application
Medeligo is an great application. It offers an easy to use interface to engage in an extensive search engine and database. The use for immediate access to specific question regarding specific pathologies makes this application particularly useful. I would recommend this product for anyone who engages in clinical or basic science oncology research.
Pediatric Neurosurgery
I have been using the app for about 6 months and have found it to be very useful. It makes valuable information on pediatric brain tumors easily available. I've also had the opportunity to share it with my residents who use it to read about upcoming cases or consults. I definitely recommend the app.
Precise, reliable, essential!
The Medeligo app is beyond anything I have used before. I used the app on the fly during my neurosurgical sub-internships nearly everyday. It’s a great way to look up information before cases and patient encounters and is an amazing resource for general study purposes. The app has become an essential for me, it’s truly helpful!
Store Rankings
Ranking History
App Ranking History not available yet
Category Rankings
App is not ranked yet
Medeligo Competitors
| Name | Downloads (30d) | Monthly Revenue | Reviews | Ratings | Recent release | |
|---|---|---|---|---|---|---|
Kidney Cancer Manager
for Renal Cell Carcinoma
|
Unlock
|
Unlock
|
0
|
|
1 year ago | |
Breast Cancer [BC]
From @Point of Care
|
Unlock
|
Unlock
|
0
|
|
6 months ago | |
Neurosurgery: What's the data?
|
Unlock
|
Unlock
|
0
|
|
2 years ago | |
Washington Manual of Oncology
Cancer Tx in Outline Format
|
Unlock
|
Unlock
|
0
|
|
2 years ago | |
Bladder Cancer Manager
|
Unlock
|
Unlock
|
0
|
|
1 year ago | |
DeepThink PTB
|
Unlock
|
Unlock
|
0
|
|
2 years ago | |
Doc2Dr ObGyn
Secure Communication for Docs
|
Unlock
|
Unlock
|
0
|
|
3 weeks ago | |
Ehrinc User
|
Unlock
|
Unlock
|
0
|
|
1 year ago | |
ALTAI Oncology
Protocols, Staging, and More
|
Unlock
|
Unlock
|
0
|
|
1 week ago | |
HealthBook Plus
Own your health.
|
Unlock
|
Unlock
|
0
|
|
1 month ago |
Medeligo Installs
Last 30 days
Medeligo Revenue
Last 30 daysMedeligo Revenue and Downloads
Gain valuable insights into Medeligo performance with our analytics.
Sign up now to access downloads, revenue, and more.
Sign up now to access downloads, revenue, and more.
App Info
- Category
- Medical
- Publisher
- LiveMed Media
- Languages
- English
- Recent release
- 1.5.4 (2 years ago )
- Released on
- Feb 19, 2016 (8 years ago )
- Also available in
- United States, Poland, Italy, Japan, South Korea, Kuwait, Lebanon, Malta, Mexico, Malaysia, Nigeria, Netherlands, Norway, New Zealand, Peru, Philippines, Pakistan, India, Portugal, Romania, Russia, Saudi Arabia, Sweden, Singapore, Slovenia, Thailand, Türkiye, Taiwan, Ukraine, Vietnam, South Africa, Denmark, Argentina, Austria, Australia, Azerbaijan, Belgium, Brazil, Belarus, Canada, Switzerland, Chile, China, Colombia, Czechia, Germany, United Arab Emirates, Dominican Republic, Algeria, Ecuador, Egypt, Spain, Finland, France, United Kingdom, Greece, Hong Kong SAR China, Hungary, Indonesia, Ireland, Israel
- Last Updated
- 2 months ago
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.